Pertzye Capsule, Delayed Release
Product Images NDC 59767-024

11 FDA label images from Digestive Care, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Pertzye (NDC 59767-024). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Digestive Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

24000 Bottle 80 Ct (59767 024 01 Bottle Label)

24000 Bottle 80 Ct (59767 024 01 Bottle Label)
Drug information panel for Pertzye (pancrelipase) delayed-release capsules, specifying dosage by lipase units and contents of protease and amylase. Includes dosage instructions, warnings, pharmacist dispensing instructions, storage information, manufacturing details by Digestive Care, Inc. in Bethlehem, PA, and patent numbers. Contains guide for proper capsule use and pharmacist medication guide dispensing.*
FDA Label Image

24000 Bottle 200 Ct (59767 024 02 Bottle Label)

24000 Bottle 200 Ct (59767 024 02 Bottle Label)
Label for Pertzye (pancrelipase) delayed-release capsules, showing strength of 24,000 USP Units of lipase, 86,250 USP Units of protease, and 90,750 USP Units of amylase per capsule. The label indicates a carton containing 200 capsules, manufactured by Digestive Care, Inc., Bethlehem, PA. Storage instructions and pharmacist dispensing directions are also included.*
FDA Label Image

Figure A

Figure A
An instructional illustration showing hands opening a capsule and emptying its contents into a bowl. The granules or powder inside the capsule are visibly falling into the bowl. This image likely demonstrates how to administer a medication in capsule form by mixing the contents.*
FDA Label Image

Figure B

Figure B
An instructional illustration showing a hand holding a small capsule open and another hand using a spoon to pour powder into the capsule body. This likely demonstrates how to open the capsule and empty its contents.*
FDA Label Image

Figure C

Figure C
An instructional illustration showing a hand holding a syringe with the thumb positioned on the plunger, demonstrating how to hold and use the syringe for injection or aspiration.*
FDA Label Image

Figure D

Figure D
An instructional line drawing illustrating the administration of a rectal enema using a syringe-like device inserted into the lower abdomen area of a person lying down. The image emphasizes the correct hand positioning and device placement for delivering the medication.*
FDA Label Image

4000 Bottle 100 Ct (Ndc 59767 004 01 Bottle Label)

4000 Bottle 100 Ct (Ndc 59767 004 01 Bottle Label)
Pertzye pancrelipase delayed-release capsules label, showing a strength of 4,000 USP Units of lipase, 14,375 USP Units of protease, and 15,125 USP Units of amylase per capsule. The label includes dosage and storage instructions, a barcode, manufacturer information for Digestive Care, Inc., Bethlehem, PA, and mentions the product is prescription only. The package size is 100 capsules.*
FDA Label Image

8000 Bottle 100 Ct (Ndc 59767 008 01 Bottle Label)

8000 Bottle 100 Ct (Ndc 59767 008 01 Bottle Label)
Label for Pertzye delayed-release capsules, containing pancrelipase. The label indicates dosage by lipase units at 8,000 USP units per capsule. It includes protease (28,750 USP units) and amylase (30,250 USP units) contents. The label also has warnings about swallowing capsules whole and storage instructions. Manufactured by Digestive Care, Inc. in Bethlehem, PA, USA.*
FDA Label Image

8000 Bottle 250 Ct (Ndc 59767 008 02 Bottle Label)

8000 Bottle 250 Ct (Ndc 59767 008 02 Bottle Label)
Label for PERTZYE delayed-release capsules containing pancrelipase, a human prescription oral capsule. This label corresponds to a 250 capsule bottle containing 8,000 USP Units of lipase, 28,750 USP Units of protease, and 30,250 USP Units of amylase per capsule. Manufactured by Digestive Care, Inc. in Bethlehem, PA. The label includes storage instructions, pharmacist dispensing information, and a barcode.*
FDA Label Image

16000 Bottle 100 Ct (Ndc 59767 016 01 Bottle Label)

16000 Bottle 100 Ct (Ndc 59767 016 01 Bottle Label)
Label for PERTZYE delayed-release capsules containing pancrelipase, manufactured by Digestive Care, Inc. The label shows that each capsule contains 16,000 USP units of lipase, 57,500 USP units of protease, and 60,500 USP units of amylase. It includes dosage, administration, storage instructions, and barcodes, with space for lot number and expiration date. The package contains 100 capsules.*
FDA Label Image

16000 Bottle 250 Ct (Ndc 59767 016 02 Bottle Label)

16000 Bottle 250 Ct (Ndc 59767 016 02 Bottle Label)
Label for PERTZYE (pancrelipase) delayed-release capsules, Rx only, containing 16,000 USP Units of lipase, 57,500 USP Units of protease, and 60,500 USP Units of amylase. The label states a bottle count of 250 capsules and is manufactured by Digestive Care, Inc. Storage instructions and warnings about swallowing capsules whole are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.